Gerresheimer stock gains as investors focus on AGM pivot and 2026 guidance

Gerresheimer stock is trading around the upper 20-euro range as investors digest the recent AGM-approved portfolio shift and revenue guidance for 2026, with the shares modestly above some analyst fair value estimates.

Gerresheimer stock (ISIN DE000A0LD6E6) recently closed at 28.36 euros on Xetra as of September 3, 2026, reflecting a daily gain of 1.65 percent according to German market data compiled by Aktiencheck and summarized by Ad Hoc News.

AGM-backed portfolio shift and debt focus

At Gerresheimer's latest annual general meeting, shareholders approved all resolutions, including the divestment of plastics units to Apax that together represent a portfolio pivot of around EUR 1.5 billion, as reported by Ad Hoc News on September 3, 2026.

According to an Ad Hoc News corporate update, the share price has been quietly recovering, trading around 27.90 euros in recent sessions, roughly 5.4 percent above its level a week earlier, giving investors some confidence that the AGM decisions are being digested positively by the market.

Revenue guidance and valuation context

For the fundamental picture, a sector overview by Spherical Insights on September 4, 2026 highlights that Gerresheimer reported revenue of EUR 2.321 billion in fiscal year 2025, supported by strong demand for drug-delivery devices and syringes, and that management expects 2026 revenue of approximately EUR 2.3 to 2.4 billion.

The same Spherical Insights analysis notes that within the company, one major segment reported EUR 986.2 million in FY2025 revenue while the Drug Delivery Systems segment generated EUR 438.8 million, illustrating a diversified revenue base in pharmaceutical packaging and drug delivery.

Ad Hoc News, citing data compiled from Simply Wall St and German market sources, points out that a fair value estimate for Gerresheimer shares stands at 25.26 euros, meaning the recent closing price of 28.36 euros as of September 3, 2026 is modestly above that valuation benchmark by about 12.3 percent.

Drug-delivery devices as a growth driver

Gerresheimer is positioned as a global pharmaceutical packaging and drug-delivery company, with Spherical Insights highlighting its role in the worldwide disposable prefilled syringes market and its offering of prefillable syringe solutions for injectable medicines, biologics and vaccines.

The research overview indicates that demand for prefilled syringes and other drug-delivery devices has been a key factor behind the FY2025 revenue figure of EUR 2.321 billion, and that management's 2026 guidance of EUR 2.3 to 2.4 billion assumes continued robust demand from pharma and biotech customers.

Stock performance and market context

According to a market snapshot drawn from Yahoo Finance's listing overview, Gerresheimer AG (ticker GXI.DE) is currently associated with a market capitalization of about EUR 963.7 million, illustrating the company's mid-cap status within the German equity market.

The Ad Hoc News corporate coverage notes that Gerresheimer shares trade on Xetra in euros and have recently been quoted around 27.90 to 28.36 euros in early September 2026, a level that sits modestly above the 25.26-euro fair value estimate discussed in the Simply Wall St-based analysis and indicates that investors are willing to pay a valuation premium while the AGM-backed portfolio pivot and 2026 revenue guidance are implemented.

Gerresheimer stock at a glance

• Company: Gerresheimer AG
• ISIN: DE000A0LD6E6
• WKN: A0LD6E
• Ticker: GXI.DE
• Trading venue: Xetra
• Price (as of September 3, 2026): 28.36 EUR
• Market capitalization: 963.7 million EUR (as of September 3, 2026)
• Sector / Industry: Health care equipment and services, pharmaceutical packaging
• Index membership: MDAX